Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
NexImmune (NEXI)
OTHER OTC:NEXI
Holding NEXI?
Track your performance easily
NEXI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.20 - $28.69
Previous Close$0.23
Volume1.99K
Average Volume (3M)3.77K
Market Cap
$320.77K
Enterprise Value-$2.10M
Total Cash (Recent Filing)$2.42M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)0.0
Beta1.95
Next Earnings
Aug 07, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-244.27
Shares Outstanding1,394,671
10 Day Avg. Volume2,669
30 Day Avg. Volume3,773
Standard Deviation0.93
R-Squared0.00762
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.46
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.11
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
NexImmune News
PremiumCompany Announcements
NexImmune Dissolution Progresses with New Sole President
PremiumCompany Announcements
NexImmune Announces Leadership Shift in Financial Management
PremiumCompany Announcements
NexImmune Announces New Offerings in Recent Press Release
PremiumCompany Announcements
NexImmune Delays Liquidation Vote for Financing Review
PremiumCompany Announcements
NexImmune Equity Sales: Unregistered Securities and Private PlacementPremiumCompany Announcements
NexImmune Secures Funding Through Equity and Warrant Sales
PremiumCompany Announcements
NexImmune Ends Stock Sale Agreement, Raises $5.1 MillionOwnership Overview
<0.01% Insiders
0.36% Mutual Funds
7.35% Other Institutional Investors
92.29% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
NEXI FAQ
What was NexImmune’s price range in the past 12 months?
NexImmune lowest stock price was $0.20 and its highest was $28.69 in the past 12 months.
What is NexImmune’s market cap?
Currently, no data Available
When is NexImmune’s upcoming earnings report date?
NexImmune’s upcoming earnings report date is Aug 07, 2024 which is 137 days ago.
How were NexImmune’s earnings last quarter?
NexImmune released its earnings results on May 13, 2024. The company reported -$2.461 earnings per share for the quarter, missing the consensus estimate of N/A by -$2.461.
Is NexImmune overvalued?
According to Wall Street analysts NexImmune’s price is currently Overvalued.
Does NexImmune pay dividends?
NexImmune does not currently pay dividends.
What is NexImmune’s EPS estimate?
NexImmune’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NexImmune have?
NexImmune has 1,394,671 shares outstanding.
What happened to NexImmune’s price movement after its last earnings report?
NexImmune reported an EPS of -$2.461 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.197%.
Which hedge fund is a major shareholder of NexImmune?
Among the largest hedge funds holding NexImmune’s share is Slate Path Capital LP. It holds NexImmune’s shares valued at N/A.
---
NexImmune Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 37.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 9.3%
Last 30 Days ▼ 9.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-92.78%
12-Months-Change
Fundamentals
Return on Equity
-230.06%
Trailing 12-Months
Asset Growth
-75.03%
Trailing 12-Months
Company Description
NexImmune
NexImmune Inc is a clinical-stage biotechnology company engaged in developing immunotherapy to employ body's T cells to generate immune response that mimics natural biology. Its creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases.
---
Technical Analysis
---